drugset
drugset / Trial / NCT05949099

Study of Cryoablation and Nirogacestat for Desmoid Tumor

NCT05949099 ↗

Phase 2 Recruiting 28 enrolled Nam Bui SpringWorks Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.

Timeline

Start
2023-08-15
Primary completion
2028-02-01
Completion
2028-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirogacestat Small molecule 150 mg Oral

Indications

desmoid tumor